Increased T Lymphocyte Activation [PE] - N0000182157
Pharmacologic Class Information
Pharmacologic Code | N0000182157 |
Pharmacologic Name | Increased T Lymphocyte Activation |
Pharmacologic Uses |
|
Pharmacologic Concept | Physiologic Effects - [PE] |
Pharmacologic Concept Description | This concept refers to the tissue, organ, or organ system effects of drug generic ingredients, organized into an organ system classification hierarchy, beneath the "Physiological Effects [PE]" concept. |
NDC Products with Increased T Lymphocyte Activation
The following table contains 5 products whose active ingredient are classified under the same pharmacologic class Increased T Lymphocyte Activation [PE].
NDC | Proprietary Name | Non-Proprietary Name | Dosage Form | Route Name | Company Name | Status | |
---|---|---|---|---|---|---|---|
0003-2327 | Yervoy | Non-Proprietary Name: Ipilimumab | Injection | Intravenous | E.r. Squibb & Sons, L.l.c. | ACTIVE | |
0003-2328 | Yervoy | Non-Proprietary Name: Ipilimumab | Injection | Intravenous | E.r. Squibb & Sons, L.l.c. | ACTIVE | |
0078-0846 | Kymriah | Non-Proprietary Name: Tisagenlecleucel | Injection, Suspension | Intravenous | Novartis Pharmaceuticals Corporation | ACTIVE | |
0078-0958 | Kymriah | Non-Proprietary Name: Tisagenlecleucel | Injection, Suspension | Intravenous | Novartis Pharmaceuticals Corporation | ACTIVE | |
71287-119 | Yescarta | Non-Proprietary Name: Axicabtagene Ciloleucel | Suspension | Intravenous | Kite Pharma, Inc. | ACTIVE |